Haleos Labs Limited

Haleos Labs Limited Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Haleos Labs Limited

₹ 1,358 -1.91%
08 Jun 1:03 p.m.
smslife.in BSE: 540679 NSE: HALEOSLABS
About

Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates[1]

Key Points

Business Overview:[1][2][3]
The company is the demerged entity of SMS Pharmaceuticals Ltd. It has a diversified product portfolio focused on the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates, with offerings spanning several therapeutic segments, including gastro-intestinal, anti-ulcer, anti-hypertensive, erectile dysfunction, anti-convulsant, anti-infective, and more

Website BSE NSE
  • Market Cap ₹ 410 Cr.
  • Current Price ₹ 1,358
  • High / Low ₹ 1,778 / 1,050
  • Stock P/E 23.1
  • Book Value ₹ 710
  • Dividend Yield 0.11 %
  • ROCE 10.6 %
  • ROE 8.64 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • The company has delivered a poor sales growth of 2.95% over past five years.
  • Company has a low return on equity of 9.28% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
65.55 74.56 67.84 71.23 86.37 86.57 78.50 82.88 85.43 79.04 77.84 80.72 63.38
63.03 69.43 58.36 62.21 75.56 72.80 66.71 69.81 79.83 68.21 67.04 69.16 57.18
Operating Profit 2.52 5.13 9.48 9.02 10.81 13.77 11.79 13.07 5.60 10.83 10.80 11.56 6.20
OPM % 3.84% 6.88% 13.97% 12.66% 12.52% 15.91% 15.02% 15.77% 6.56% 13.70% 13.87% 14.32% 9.78%
4.64 0.58 0.33 0.64 2.28 0.43 1.26 0.06 2.20 1.01 0.44 0.08 0.97
Interest 1.41 1.82 2.48 2.04 2.56 2.16 1.92 1.96 1.84 1.73 1.51 1.46 1.34
Depreciation 2.12 2.53 2.55 2.55 2.62 2.50 2.57 2.56 2.62 2.63 2.68 2.69 2.66
Profit before tax 3.63 1.36 4.78 5.07 7.91 9.54 8.56 8.61 3.34 7.48 7.05 7.49 3.17
Tax % 31.96% 48.53% 34.73% 34.71% 24.91% 32.29% 29.79% 27.64% 19.76% 31.02% 29.36% 27.77% 29.65%
2.47 0.70 3.12 3.31 5.93 6.46 6.01 6.23 2.68 5.16 4.98 5.41 2.23
EPS in Rs 8.17 2.32 10.32 10.95 19.61 21.37 19.88 20.61 8.86 17.07 16.47 17.89 7.38
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 0 218 213 344 257 260 346 315 300 333 301
0 0 189 200 312 233 230 314 289 265 289 261
Operating Profit 0 0 28 13 33 24 30 31 26 35 44 40
OPM % 13% 6% 9% 9% 11% 9% 8% 12% 13% 13%
0 0 2 3 2 2 1 14 5 4 4 1
Interest 0 0 6 4 5 5 5 5 5 9 8 6
Depreciation 0 0 6 6 6 7 7 8 8 10 10 11
Profit before tax 0 0 18 6 24 13 19 33 18 19 30 25
Tax % 30% -2% 30% 31% 32% 23% 28% 32% 29% 29%
0 0 13 6 17 9 13 25 13 13 21 18
EPS in Rs 21.50 55.01 30.26 43.56 83.95 43.73 43.23 70.68 58.81
Dividend Payout % 0% 0% 3% 0% 3% 2% 3% 3% 2% 0%
Compounded Sales Growth
10 Years: %
5 Years: 3%
3 Years: -2%
TTM: -10%
Compounded Profit Growth
10 Years: %
5 Years: 6%
3 Years: 16%
TTM: -17%
Stock Price CAGR
10 Years: %
5 Years: 16%
3 Years: 38%
1 Year: 8%
Return on Equity
10 Years: 11%
5 Years: 9%
3 Years: 9%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.01 0.01 0.01 3 3 3 3 3 3 3 3 3
Reserves -0 -0 82 85 102 110 123 148 161 173 194 212
0 0 26 27 47 50 45 62 87 92 82 95
0 0 67 61 98 66 101 99 86 80 80 94
Total Liabilities 0 0 175 177 251 229 272 312 337 348 358 403
0 0 73 69 88 94 101 99 140 138 150 190
CWIP 0 0 0 7 1 2 3 21 1 6 0 1
Investments 0 0 0 5 26 26 26 23 23 23 23 23
0 0 102 95 135 106 142 169 174 181 184 189
Total Assets 0 0 175 177 251 229 272 312 337 348 358 403

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 0 20 8 27 14 22 -15 5 15 28 38
0 0 -8 -7 -43 -13 -6 -7 -28 -14 -14 -49
0 0 -12 -1 18 -2 -8 15 23 -1 -14 11
Net Cash Flow 0 0 -0 0 2 -1 8 -8 -1 0 0 0
Free Cash Flow 0 0 12 4 5 1 14 -30 -24 1 14 -11
CFO/OP 87% 66% 103% 70% 88% -23% 31% 51% 82% 111%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 65 46 39 31 42 36 53 60 71 66
Inventory Days 133 135 117 138 154 143 154 168 131 183
Days Payable 168 122 133 91 147 124 105 111 99 141
Cash Conversion Cycle 30 60 23 78 48 54 102 116 102 108
Working Capital Days 43 41 20 27 31 44 65 61 57 57
ROCE % 0% 46% 9% 22% 12% 14% 13% 9% 11% 14% 11%

Insights

In beta
Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Total Employee Strength
Number

Log in to view insights

Please log in to see hidden values.

Login
R&D Expenditure
INR Lakhs
Total Installed Reactor Capacity (Consolidated)
KL
Number of Active APIs in Portfolio
Number
Revenue Contribution from Ranitidine HCl
%
Annual US Drug Master File (USDMF) Filings
Number
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
70.32% 70.32% 70.68% 71.19% 71.40% 71.40% 71.40% 71.40% 71.40% 71.40% 71.79% 72.10%
0.00% 0.00% 0.00% 0.00% 0.01% 0.02% 0.00% 0.00% 0.03% 0.00% 0.00% 0.00%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.03% 0.29% 0.30%
29.68% 29.68% 29.31% 28.81% 28.59% 28.57% 28.59% 28.60% 28.56% 28.57% 27.91% 27.59%
No. of Shareholders 8,4758,4438,2338,1167,8617,8497,6267,4797,4127,5217,1256,937

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Jul 2025
    Transcript
    AI Summary
    PPT